Sign in Subscribe

retrospective

A collection of 92 issues

Age-stratified analysis reveals CEMIP elevation in early-onset CRC

Skip to content The CRC Digest ◇ RESEARCH Age-stratified analysis reveals CEMIP elevation in early-onset CRC Transcriptomic profiling identified CEMIP, NKD2, and FOXQ1 as elevated in colorectal cancer diagnosed before age 50, with CEMIP showing the strongest association with survival outcomes. (Genes) This content is informational only and does not constitute

CEMIP identified as candidate biomarker in early-onset colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH CEMIP identified as candidate biomarker in early-onset colorectal cancer Researchers identified CEMIP as elevated in colorectal cancer diagnosed before age 50 and associated with poorer overall survival, with evidence linking it to PTCH1-related Hedgehog signaling pathways. (Genes) This content is informational only and

Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC

Skip to content The CRC Digest ◇ RESEARCH Kazakhstan Study Links KRAS Mutation Detection Methods to Survival in Stage II-IV CRC A 332-patient cohort study compared KRAS variant detection by real-time and digital PCR in tumor tissue and plasma, examining associations with overall survival across stage II-IV disease. (Genes) This content

Case series documents bowel stenosis following immunotherapy in dMMR colorectal cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Case series documents bowel stenosis following immunotherapy in dMMR colorectal cancer A case series documents bowel stenosis following immunotherapy in patients with mismatch repair deficient colorectal cancer. (Clinical Colorectal Cancer) This content is informational only and does not constitute medical advice.

Case report: POLE mutation combined with dMMR/MSI

Skip to content The CRC Digest ▸ TREATMENT Case report: POLE mutation combined with dMMR/MSI (Am J Ther) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Single-port versus multi-port robotic surgery for colorectal cancer

Skip to content The CRC Digest ♥ LIVING WITH CRC Single-port versus multi-port robotic surgery for colorectal cancer In a propensity score-matched analysis of 104 patients per group with stage I-III CRC, researchers compared single-port and multi-port robotic surgery. Single-port robotic surgery may reduce incision burden compared with multi-port robotic surgery.

Case report: POLE-mutated, dMMR/MSI colorectal cancer

Skip to content The CRC Digest ▸ TREATMENT Case report: POLE-mutated, dMMR/MSI colorectal cancer (Am J Ther) This content is informational only and does not constitute medical advice. Always consult your oncologist or care team. © 2026 The CRC Digest — crcdigest.com

Genetic Changes Between Primary and Recurrent Rectal Cancer May Reveal New Treatment Targets

Skip to content The CRC Digest ◇ RESEARCH Genetic Changes Between Primary and Recurrent Rectal Cancer May Reveal New Treatment Targets A study of 15 matched pairs of primary and locally recurrent rectal cancers found that recurrent tumors acquired new genetic alterations not present in the original tumor, including potentially actionable

Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy

Skip to content The CRC Digest ♥ LIVING WITH CRC Study Identifies Risk Factors for Serious Intestinal Side Effect With CAPOX Chemotherapy Researchers examined the incidence and risk factors of non-neutropenic enterocolitis—a serious intestinal inflammation—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin (CAPOX) chemotherapy. (Clinical Colorectal Cancer) This

Study compares biologic agents in liver-limited RAS wild-type disease

Skip to content The CRC Digest ▸ TREATMENT Study compares biologic agents in liver-limited RAS wild-type disease A retrospective analysis of 241 patients with RAS wild-type metastatic colorectal cancer confined to the liver compared outcomes among patients treated with first-line chemotherapy plus panitumumab, cetuximab, or bevacizumab, evaluating depth of response, objective